We demonstrated that inhibition of IL-6 signaling by MR16-1 treatment resulted in not only the reduction of elevated hepcidin levels which led to the improvement of anemia status but also the systemic amelioration of disease symptoms. This evidence concerns the gene HAMP and anemia.